Skip to content

Public FDA record

Z-0992-04: ABX Diagnostics Minotrol 16 Hematology Controls, Normal and High, in vials distributed by ABX Diagnostics

Recall record Z-0992-04 for R & D Systems,Inc. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0992-04
Company in FDA record
R & D Systems,Inc
FDA classification date
Jul 20, 2004
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 20, 2026
Recall classification
Unknown — no matched enforcement classification

Reason stated in the source

Clots in hematology controls resulted in low red blood cell counts when used in blood analyzers because control values were outside the expected range due to the clotting which took place after manufacturing.

Source facts

Action
Recall letters dated April 15, 2004 instructed consignees not to use the products to verify their analyzers and stated that the recalling firm is working on providing replacement products.
Initiated
2004-04-15
Root cause
Other
Terminated
2004-06-24
Distribution
The products were shipped to California, France and Japan.
Recall number
Z-0992-04
Recall status
Terminated
CDRH record ID
33037
FDA classified
2004-07-20
Recall event number
29044

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗